CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for nerve disease: immune therapy trial targets long-term control
Disease control Recruiting nowThis study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher o…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Engineered immune cells take on multiple sclerosis and other nerve diseases
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
New hope for nerve disease patients: drug may replace monthly IV treatments
Disease control Recruiting nowThis study tests a new drug called riliprubart against standard IVIg treatment in 160 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. Participants currently on IVIg will be randomly assigned to receive either r…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New CIDP drug empasiprubart enters final phase of testing
Disease control Recruiting nowThis phase 3 trial tests whether empasiprubart, given by IV infusion, can help adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The study will enroll 160 participants. For the first 6 months, some get the …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug could replace standard infusions for nerve disorder
Disease control Recruiting nowThis study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 218 adults who have used IVIg before will receive either t…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug IMVT-1402 aims to stop CIDP relapses in Mid-Stage trial
Disease control Recruiting nowThis Phase 2b study tests whether the drug IMVT-1402 can help adults with CIDP, a nerve disorder causing weakness and numbness. About 162 participants will receive either the drug or a placebo weekly for up to 52 weeks. The main goal is to see if the drug keeps the disease from w…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to stop CIDP relapses in its tracks
Disease control Recruiting nowThis Phase 3 trial tests whether the drug claseprubart (DNTH103) can prevent relapses in adults with CIDP, a nerve disorder that causes weakness and disability. About 256 participants will receive either the drug or a placebo. The main goal is to see how long it takes for symptom…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Blood-Filtering therapy tested for nerve disease
Disease control Recruiting nowThis study is testing a blood-filtering treatment called immunoadsorption for people with CIDP, a nerve disorder causing weakness and numbness. About 140 adults who did not get better with standard treatments will be observed for 18 months. The goal is to see if immunoadsorption …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: University of Ulm • Aim: Disease control
Last updated Jun 26, 2026 16:23 UTC
-
Shocking muscles to move: new exercise hope for nerve disease patients
Symptom relief Recruiting nowThis study tests whether whole-body electrical muscle stimulation (WB-EMS) can help adults with neuromuscular diseases like ALS, SMA, and muscular dystrophy exercise safely. Because these conditions weaken the nerves that control muscles, traditional exercise is often too hard. W…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: NA • Sponsor: University of Missouri-Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Body fat may change how well immune therapy works
Knowledge-focused Recruiting nowThis study looks at how a person's body composition (fat and muscle) affects the way immunoglobulin G (IgG) moves through the body after being given through a vein or under the skin. Researchers will enroll 20 adults with a nerve condition called CIDP who already receive IgG ther…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC